Recordati Industria Chimica E Farmaceutica S.p.a.

Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

Chemi S.p.a.

Recordati Ireland Limited

Italfarmaco Sud S.p.a.

Fausto Bonifacio

Oreste Piccolo

Cristina Crescenzi

Lorenzo De Ferra

Pietro Massardo

Maria Donnarumma

Dimitri Ippoliti

Maria Ornella Tinti

Sergio Penco

Amedeo Leonardi

Francesco Campana

Gianluca De Iasi

Guido Cifarelli

Sandra Rondinini

Patrizia R Mussini

This invention relates to crystalline polymorphs of sertraline hydrocloride, i.e. (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphtalenamine hydrochloride, denominated form I, II and V, and methods for their preparation.

Methods for preparing sertraline hydrochloride polymorphs

This invention relates to a method for the preparation of sertraline hydrochloride, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphtalenamine hydrochloride, in its crystalline form II.

Sertraline hydrochloride form II and methods for the preparation thereof

The invention describes novel lercanidipine crude Forms (A) and (B), novel lercanidipine hydrochloride crystalline Forms (I) and (II) obtained from said crude Forms, pharmaceutical, antihypertensive compositions containing as active agent at least one of the lercanidipine hydrochloride crystalline Forms (I) and (II) and methods of use thereof.

Crude and crystalline forms of lercanidipine hydrochloride

The present invention describes a process for the industrial production of L-carnitine, comprising the enantioselective reduction of an alkyl 4-chloro-3-oxobutyrate or 4-chloro-3-oxobutyramide. The optically active 3-hydroxy derivative thus obtained is reacted with trimethylamine, obtaining crude L-carnitine, which is then finally purified. The catalyst used for the reduction is a complex of ruthenium bound to a penta-atomic bis-heteroaromatic system. The reduction reaction, performed in controlled conditions of hydrogen pressure, substrate concentration, temperature, and substrate: catalyst molar ratio, enables 4-chloro-3-hydoxybutyrate or 4-chloro-hydroxybutyamide to be obtained in a high yield. The process described, which leads to L-carnitine being obtained, is easily applicable on an industrial scale.

Industrial process for the production of L-carnitine

A process for fractionating deacylated glycerophospholipids of the formula (I): ##STR1## wherein R is a negative charge; a hydrogen atom; a CH.sub.2 CH.sub.2 NR.sup.1 R.sup.2 residue wherein R.sup.1 and R.sup.2, which are the same or different, are H or C.sub.1 -C.sub.4 alkyl; a CH.sub.2 CH.sub.2 N.sup.+ (CH.sub.3).sub.3 residue; a CH.sub.2 CH(NH.sub.2)COOH residue or a residue of the formula: ##STR2## and X is OH or 0.sup.-, is described. The process involves subjecting an aqueous or hydroalcoholic mixture of two or more of the deacylated glycerophospholipids to electrodialysis in an electrolytic cell comprising a number of compartments. The compartments are separated by cation-exchange membranes, anion-exchange membranes or both cation-exchange and anion-exchange membranes, at a pH effective to differentiate the deacylated glycerophospholipids.

Process for the preparation of glycerophospholipids

A process for the preparation of highly pure deacylated glycerophosphorylcholine, glycerophosphorylethanolamine and glicerophosphorylserine starting from mixtures of the corresponding acylated derivatives.

Growing community of inventors

Latina, Italy

Fausto Bonifacio